Karla Santo

Dr. Karla Santo

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2015 in JAMA
Verified
Journal Article
Open access
PDF file
CCClara Chow
Clara Chow
JRJulie Redfern
Julie Redfern
GHGraham S. Hillis
Graham S. Hillis
JTJay Thakkar
Jay Thakkar
KSKarla Santo
Karla Santo
ATAravinda Thiagalingam
Aravinda Thiagalingam
Globally, cardiovascular disease is the leading cause of death and disease burden.1 Many treatments and treatment strategies are proven to reduce the risk of major cardiovascular events. Interventions that modify lifestyle factors are among the most effective but are poorly adhered to.2

1 March 2016 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
JTJay Thakkar
Jay Thakkar
RKRahul Kurup
Rahul Kurup
TLTracey-Lea Laba
Tracey-Lea Laba
KSKarla Santo
Karla Santo
ATAravinda Thiagalingam
Aravinda Thiagalingam
CCClara K. Chow
Clara K. Chow
Adherence is defined as the extent to which a patient correctly follows a prescribed therapy. Adherence is the medically preferred term because it reflects active involvement of the patient and a therapeutic alliance between the patient and his or her physician.1 This term is in contrast to compliance, which reflects more unidirectional connotations.1,2 Adherence to long-term therapies in developed countries is typically reported to be approximately 50% at 1 year after initiation of therapy, with worse rates in lower socioeconomic groups and in developing countries.3,4 Poor adherence has been linked to successive hospitalizations, increased need for medical interventions, morbidity, and mortality.5 In addition, medication nonadherence results in increased health care cost, with estimates from North America of approximately $100 billion being spent annually and $2000 spent per patient per year in excess physician visits.6

2 December 2016 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
KSKarla Santo
Karla Santo
SRSarah S Richtering
Sarah S Richtering
JCJohn Chalmers
John Chalmers
ATAravinda Thiagalingam
Aravinda Thiagalingam
CCClara Chow
Clara Chow
JRJulie Redfern
Julie Redfern
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

27 August 2018 in Heart
Verified
Journal Article
Closed access
PDF file
KSKarla Santo
Karla Santo
ASAnna Singleton
Anna Singleton
KRKris Rogers
Kris Rogers
ATAravinda Thiagalingam
Aravinda Thiagalingam
JCJohn Chalmers
John Chalmers
JRJulie Redfern
Julie Redfern
Objective The aim of the MEDication reminder APPs to improve medication adherence in Coronary Heart Disease Study was to evaluate the effectiveness and feasibility of using publicly available high-quality medication reminder applications (apps) to improve medication adherence compared with usual care in patients with coronary heart disease (CHD). An additional aim was to examine whether an app with additional features improved adherence further. Methods Patients with CHD (n=163) were randomised to one of three groups: (1) usual care, (2) a basic app or (3) an advanced app with interactive/customisable features. The primary analysis compared usual care versus app use on the primary outcome of the 8-item Morisky Medication Adherence Scale (MMAS-8) at 3 months. Secondary outcomes included blood pressure and cholesterol levels. Results The mean age was 57.9 years and 87.7% were male. At 3 months, patients using an app had higher adherence (mean MMAS-8 score 7.11) compared with the usual care group (mean MMAS-8 score 6.63) with a mean difference between groups of 0.47 (95% CI 0.12 to 0.82, p=0.008). There was no significant difference in patients using the basic app versus the advanced app (mean difference −0.16, 95% CI −0.56 to 0.24, p=0.428). There were no significant differences in secondary clinical outcome measures. Conclusion Patients with CHD who used medication reminder apps had better medication adherence compared with usual care, and using apps with additional features did not improve this outcome further. These data suggest medication apps are likely to help patients with chronic health conditions adhere to medicines, but further examination of whether such benefits are sustained is warranted. Clinical trial registration number ACTRN12616000661471; Results.

14 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JRJulie Redfern
Julie Redfern
KSKarla Santo
Karla Santo
GCGenevieve Coorey
Genevieve Coorey
JTJay Thakkar
Jay Thakkar
MHMaree L. Hackett
Maree L. Hackett
CCClara K Chow
Clara K Chow
Many studies have now demonstrated the efficacy of text messaging in positively changing behaviours. We aimed to identify features and factors that explain the effectiveness of a successful text messaging program in terms of user engagement, perceived usefulness, behavior change and program delivery preferences. Mixed methods qualitative design combining four data sources; (i) analytic data extracted directly from the software system, (ii) participant survey, (iii) focus groups to identify barriers and enablers to implementation and mechanisms of effect and (iv) recruitment screening logs and text message responses to examine engagement. This evaluation was conducted within the TEXT ME trial—a parallel design, single-blind randomized controlled trial (RCT) of 710 patients with coronary heart disease (CHD). Qualitative data were interpreted using inductive thematic analysis. 307/352 (87% response rate) of recruited patients with CHD completed the program evaluation survey at six months and 25 participated in a focus group. Factors increasing engagement included (i) ability to save and share messages, (ii) having the support of providers and family, (iii) a feeling of support through participation in the program, (iv) the program being initiated close to the time of a cardiovascular event, (v) personalization of the messages, (vi) opportunity for initial face-to-face contact with a provider and (vii) that program and content was perceived to be from a credible source. Clear themes relating to program delivery were that diet and physical activity messages were most valued, four messages per week was ideal and most participants felt program duration should be provided for at least for six months or longer. This study provides context and insight into the factors influencing consumer engagement with a text message program aimed at improving health-related behavior. The study suggests program components that may enhance potential success but will require integration at the development stage to optimize up-scaling. Australia and New Zealand Clinical Trials Registry, ACTRN12611000161921.

9 October 2019 in Open Heart
Verified
Journal Article
Open access
PDF file
Sheikh Mohammed Shariful IslamSheikh Mohammed Shariful Islam
Sheikh Mohammed Shariful Islam
AFAndrew J Farmer
Andrew J Farmer
KBKirsten Bobrow
Kirsten Bobrow
RMRalph Maddison
Ralph Maddison
RWRobyn Whittaker
Robyn Whittaker
CCClara Chow
Clara Chow
Background A variety of small mobile phone text-messaging interventions have indicated improvement in risk factors for cardiovascular disease (CVD). Yet the extent of this improvement and whether it impacts multiple risk factors together is uncertain. We aimed to conduct a systematic review and individual patient data (IPD) meta-analysis to investigate the effects of text-messaging interventions for CVD prevention. Methods Electronic databases were searched to identify trials investigating a text-messaging intervention focusing on CVD prevention with the potential to modify at least two CVD risk factors in adults. The main outcome was blood pressure (BP). We conducted standard and IPD meta-analysis on pooled data. We accounted for clustering of patients within studies and the primary analysis used random-effects models. Sensitivity and subgroup analyses were performed. Results Nine trials were included in the systematic review involving 3779 participants and 5 (n=2612) contributed data to the IPD meta-analysis. Standard meta-analysis showed that the weighted mean differences are as follows: systolic blood pressure (SBP), −4.13 mm Hg (95% CI −11.07 to 2.81, p<0.0001); diastolic blood pressure (DBP), −1.11 mm Hg (−1.91 to −0.31, p=0.002); and body mass index (BMI), −0.32 (−0.49 to −0.16, p=0.000). In the IPD meta-analysis, the mean difference are as follows: SBP, −1.3 mm Hg (−5.4 to 2.7, p=0.5236); DBP, −0.8 mm Hg (−2.5 to 1.0, p=0.3912); and BMI, −0.2 (−0.8 to 0.4, p=0.5200) in the random-effects model. The impact on other risk factors is described, but there were insufficient data to conduct meta-analyses. Conclusion Mobile phone text-messaging interventions have modest impacts on BP and BMI. Simultaneous but small impacts on multiple risk factors are likely to be clinically relevant and improve outcome, but there are currently insufficient data in pooled analyses to examine the extent to which simultaneous reduction in multiple risk factors occurs. PROSPERO registration number CRD42016033236.